EH
PLX icon

Equitable Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Equitable Holdings’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.1K Hold
11,150
– – ﹤0.01% 1678
2025
Q4 		$20.1K Buy
+11,150
New +$22.8K ﹤0.01% 1570

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Equitable Holdings's PLX Position: Q1 2026 in Review

Equitable Holdings held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 11,150 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1678.

Equitable Holdings first reported a position in PLX in Q4 2025 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Equitable Holdings held 11,150 shares of Protalix BioTherapeutics worth $20.1K as of Q1 2026.
  • Equitable Holdings left its Protalix BioTherapeutics share count unchanged in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of Equitable Holdings's portfolio in Q1 2026, its #1678 holding.
  • Equitable Holdings first reported a position in Protalix BioTherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Equitable Holdings's 13F filing for Q1 2026, filed 15 May 2026.